Drugs / NNC0142-0002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00927927 | Jun 2009 → Dec 2011 | rheumatoid arthritis | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01181050 | Aug 2010 → Apr 2012 | rheumatoid arthritis | Janssen Research & Development, LLC | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0142-0002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01181050 ↗ |
| Route | Subcutaneous | “administered subcutaneously (under the skin)” NCT00927927 ↗ |